Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 06, 2020 16:01 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
December 09, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET Norwood, MA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
November 18, 2019 08:17 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company expects to report topline data from study in the summer of 2020Primary endpoint of this study is reduction in pulmonary exacerbationsStudy enrolled participants regardless of CFTR mutation...
Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London
November 12, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Presentation with live audio webcast on Wednesday, November 20th at 5:20 PM DST - Norwood, MA , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
November 11, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile...
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
November 07, 2019 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 “RESOLVE-1” study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in...
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019
November 04, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Thursday, November 7 at 8:30 a.m. ET - Norwood, MA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:...
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting
October 03, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presentedSystemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU...
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates
August 08, 2019 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU and Japan CRB-4001 on...
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Operational and Financial Results on August 8, 2019
August 01, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Thursday, August 8 at 8:30 a.m. ET - Norwood, MA, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...